Radiographic progression was not assessed in this study, but patients in both tofacitinib groups had more decreases in swollen and tender joint count, PGA of arthritis, Psoriatic Arthritis Response criteria (PsARC), and CRP levels when compared to placebo. This evidence concerns the gene CRP and arthritic joint disease.